Studies Show Psoriasis Patients Achieved Significant Levels of Skin Clearance and Improved Quality of Life after 12 Weeks of Ixekizumab Treatment
Details of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet
-- Ixekizumab met all primary and secondary objectives in two pivotal Phase III studies, demonstrating superiority to etanercept and placebo after 12 weeks of treatment for moderate-to-severe plaque psoriasis.
-- Approximately nine of 10 patients treated with ixekizumab every two weeks achieved at least 75 percent reduction in plaque psoriasis, and approximately four out of 10 patients achieved complete skin clearance.
-- More than 60 percent of patients treated with ixekizumab reported that their psoriasis no longer impacted their quality of life.
-- In these studies, the overall safety profile of ixekizumab was comparable to etanercept.